SAB Biotherapeutics (SABS) PT Raised to $10 at H.C. Wainwright
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/30/2026
- Wall Street ends lower as Alphabet revenue miss revives AI capex jitters
- Alphabet shares tumble 10% as earnings miss overshadows cloud boom
- Microsoft rises premarket as cloud strength drives earnings beat
- Caterpillar shares slump 10% despite earnings beat amid rapid AI buildout
- DoorDash to acquire Instacart in $17 billion deal
Tweet
Share
E-mailGet Alerts SABS Hot Sheet
Price: $3.23 --0%
Rating Summary:
14 Buy, 1 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 1 | Down: 21 | New: 0
Rating Summary:
14 Buy, 1 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 1 | Down: 21 | New: 0
Join SI Premium – FREE
H.C. Wainwright analyst Edward White raised the price target on SAB Biotherapeutics (NASDAQ: SABS) to $10.00 (from $1.00) while maintaining a Buy rating.
You May Also Be Interested In
- Morgan Stanley Upgrades Aixtron SE (AIXA:GR) (AIXXF) to Overweight
- First Solar (FSLR) PT Lowered to $255 at BMO Capital
- Mondelez International (MDLZ) PT Raised to $75 at TD Cowen
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
